INNOVATE Corp., through its subsidiaries, provides construction, insurance, life sciences, broadcasting, and other services in the United States, the United Kingdom, and internationally. The company models, details, fabricates, and erects structural steel for commercial and industrial, and infrastructure construction projects, including building and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, and power plants. It also fabricates trusses and girders; and fabricates and erects water pipes, water storage tanks, pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators, and various customized products. In addition, the company provides equipment for the oil and gas industry. Further, it offers long-term care, life, annuity, and other accident and health coverage; focuses on developing products for early osteoarthritis of the knee, as well as skin lightening technology; and operates over-the-air broadcasting stations and Azteca America, a Spanish-language broadcast network. The company was formerly known as HC2 Holdings, Inc. and changed its name to INNOVATE Corp. in September 2021. INNOVATE Corp. was founded in 1994 and is headquartered in New York, New York.
IPO Year:
Exchange: NYSE
Website: innovatecorp.com
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives. Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the company's clinical policy, quality, and per
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Amy Wilkinson to fill the remaining vacancy on the INNOVATE Board of Directors. "Amy brings a unique blend of management expertise and global business and policy experience, and we are confident she will help guide us in our mission to drive shareholder value across our Infrastructure, Life Sciences and Spectrum operating segments," said Avie Glazer, Chairman of INNOVATE. "Amy's leadership and strategy consulting experience advising Fortune 500 companies will be a valuable addition to our Board," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE
NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Brian Goldstein to fill a vacancy on the INNOVATE Board of Directors, effective immediately. "The addition of Brian strengthens INNOVATE's Board, bringing tax expertise and a unique perspective that will help guide the Company as we strive to optimize our best-in-class assets across our three segments – Infrastructure, Life Sciences and Spectrum – and drive long-term value for our stakeholders," said Avie Glazer, Chairman of INNOVATE. "Brian has been a valuable member of the Board at DBM Global in our Infrastructure segment, and we are confident his dee
- Appoints Two New Directors - Brian Goldstein and Holly Cindell PHOENIX, Oct. 28, 2021 (GLOBE NEWSWIRE) -- DBM Global Inc. announced today the election of two new Board members – Brian Goldstein and Holly Cindell. Current Directors James R. Roach, Michael R. Hill, Robert V. Leffler, Jr., Kenneth S. Courtis, and Wayne Barr, Jr. will also continue their service on the Board. "The DBMG Board is excited to welcome Brian Goldstein, a former partner with PWC, and Holly Cindell, a construction industry veteran, to the Board. We believe that the experience of Brian and Holly will serve to enhance shareholder value in light of our continued expansion this last year," commented Chairman of th
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
4 - INNOVATE Corp. (0001006837) (Issuer)
SC 13G/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13D/A - INNOVATE Corp. (0001006837) (Subject)
SC 13G/A - INNOVATE Corp. (0001006837) (Subject)
SC 13G/A - INNOVATE Corp. (0001006837) (Subject)
- Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31, 2025 2024 Increase / (Decrease)Revenue$274.2 $315.2 (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31, 2024 2023 Increase / (Decrease) 2024 2023 Increase / (Decrease)Revenue$236.6 $361.0
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the fourth quarter and full year 2024 on Monday, March 31, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go
- Infrastructure: DBM Global third quarter revenue of $232.8 million -- Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter -- Spectrum: Broadcasting's delivered another quarter of strong growth driven by network launches - NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the third quarter. Financial Summary (in millions, except per share amounts)Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 Increase / (Decrease) 2024 2023 Increase / (Decrease)Revenue$242.2 $375.3 (35.5)% $870.5 $1,062.0 (18.0)%
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "In
- Infrastructure: DBM Global achieved second quarter revenue of $305.2 million -- Life Sciences: R2 achieved record Glacial system sales in North America in the second quarter -- Spectrum: Broadcasting's growth driven by launch of new networks and cost-cutting efforts - NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the second quarter. Financial Summary (in millions, except per share amounts)Three Months Ended June 30, Six Months Ended June 30, 2024 2023 Increase / (Decrease) 2024 2023 Increase / (Decrease)Revenue$313.1 $368.8 (15.1)% $628.3 $686.7 (8.5)%Net income (loss) attribu
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Inv
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2024 on Tuesday, May 7, 2024, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Invest
- Infrastructure: DBM Global achieved fourth quarter revenue of $353.8 million -- Life Sciences: R2 experienced strong North America unit sales in the fourth quarter -- Spectrum: Broadcasting entered into agreements with PBS stations for new commercial opportunities with ATSC 3.0 - NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter and full year. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31, 2023 2022 Increase / (Decrease) 2023 2022 Increase / (Decrease)Revenue$361.0 $409.3 (11.8)% $1,423.0 $1,637.3 (13.1
- Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31, 2025 2024 Increase / (Decrease)Revenue$274.2 $315.2 (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31, 2024 2023 Increase / (Decrease) 2024 2023 Increase / (Decrease)Revenue$236.6 $361.0
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the fourth quarter and full year 2024 on Monday, March 31, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.The Clinical Kidney Journal in February published MediBeacon study results on measured GFR (mGFR) using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages.MediBeacon TGFR study results have been posted online in the February ahead of print section in the Journal of the American Society of Nephrology (JASN). NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today the National Medical Products Administration (NM
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal functionThe transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicityMore than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades1 NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon®
PHOENIX, Jan. 06, 2025 (GLOBE NEWSWIRE) -- DBM Global Inc. ("DBM") announces the election of new Chief Financial Officer (CFO) – Mark Koolis. Former CFO Michael R. Hill has taken a different position with DBM and has been elected as Vice President of Finance and will remain on the DBM Board of Directors. The other Officers will keep their current roles: James R. Roach – Chairman and CEO, Robert N. Waldrep – Vice President, and Scott D. Sherman – Vice President, General Counsel, and Secretary. Mr. Roach stated that "Mike Hill has served, with distinction, as CFO for DBM Global since 2000 and we are excited to have Mike continue in a different role with the Company." Mr. Roach added that
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems ("R2"), a portfolio company of INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it has achieved several impressive milestones during 2024. The growing momentum of the brand coupled with recent key partnerships has positioned the company for substantial growth across the aesthetics and wellness sectors. Celebrating the one-year anniversary of the Glacial fx platform launch, R2 Technologies has seen unparalleled success, recording a 294% increase in worldwide Glacial Skin system unit sales over the same period last y
- Infrastructure: DBM Global third quarter revenue of $232.8 million -- Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter -- Spectrum: Broadcasting's delivered another quarter of strong growth driven by network launches - NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the third quarter. Financial Summary (in millions, except per share amounts)Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 Increase / (Decrease) 2024 2023 Increase / (Decrease)Revenue$242.2 $375.3 (35.5)% $870.5 $1,062.0 (18.0)%
PHOENIX, Oct. 16, 2024 (GLOBE NEWSWIRE) -- DBM Global Inc. ("DBM Global") subsidiaries Banker Steel, a division of Schuff Steel Company ("Banker Steel") and NYC Constructors LLC ("NYCC") placed the final steel beam in Phase One of John F. Kennedy International Airport's new Terminal 6, marking the successful fabrication and erection of structural steel for the massive redevelopment project. Terminal 6 is a key component of the Port Authority of New York and New Jersey's $19 billion transformation of JFK Airport into a world-class gateway, which will include two new terminals, the modernization and expansion of two existing terminals, a new ground transportation center and an entirely new,
10-Q - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
DEFA14A - INNOVATE Corp. (0001006837) (Filer)
DEF 14A - INNOVATE Corp. (0001006837) (Filer)
10-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)
8-K - INNOVATE Corp. (0001006837) (Filer)